Boston, May 1: India’s emergence as a global pharmaceutical hub is entering a new phase, driven by innovation, vaccine leadership, and enhanced clinical capabilities. This insight comes from Elias Zerhouni, former director of the National Institutes of Health and current vice president of OPKO Health.
Zerhouni noted that the health and biotechnology collaboration between India and the United States has strengthened significantly over the years. This partnership is evolving from mere manufacturing to innovation-based collaboration.
He stated, “The presence of Indian companies is rapidly increasing—such as Lupin Limited, Sun Pharmaceutical Industries, and many others. This relationship is improving as India is now seen not just as a manufacturing hub but also as an innovative nation.”
Zerhouni emphasized India’s stronghold in the generics and active pharmaceutical ingredients (API) sectors, which remain the backbone of the global drug supply. He remarked, “India’s strength in the API sector is substantial… these come primarily from India or China.”
However, he stressed that India’s role has transcended generics. He highlighted India’s capacity for vaccine production as crucial on a global scale, referencing the Serum Institute of India. He said, “Vaccination worldwide would be extremely challenging without India’s contributions.”
He praised the Indian approach of “frugal innovation,” which focuses on developing effective solutions at low costs. “Such innovation should not be so expensive that it becomes inaccessible—this is part of India’s culture,” he added.
Reflecting on lessons learned from the COVID-19 pandemic, he pointed out that it exposed vulnerabilities in the global supply chain and compelled nations to rethink health security. He stated, “We found that we were not fully prepared for a global health emergency.”
As two large democracies, India and the U.S. rely more on the private sector than government plans to address these challenges. He noted, “There is no grand master plan… collaboration is driven by goodwill and economic incentives.”
Sharing his experiences, he mentioned that bureaucratic processes in both countries remain a challenge. He recalled discussions with former Prime Minister Manmohan Singh regarding delays in grant approvals. “We are democratic, but bureaucracy has its role,” he said.
Regarding clinical trials, he acknowledged that India is still in the early stages but is improving. “Clinical trials are highly sensitive… capable sites and a robust regulatory framework are essential,” he explained.
He also mentioned the increasing trend of investment moving away from China globally, which is benefiting India. Collaboration in medical technology and biomedical research is on the rise.
Discussing challenges in the health sector, he pointed out that high drug prices in the U.S. are a significant issue, while India remains focused on providing health services to as many people as possible.
On the role of artificial intelligence, he said it has improved the speed and quality of research, but it has not yet proven decisive in making entirely new discoveries.
Zerhouni described biotechnology as entering a “multipolar” era, where India, China, and other countries contribute to innovation. He concluded, “I don’t care where the treatment comes from; my goal is for patients to recover.”
My name is Narendra Jijhontiya. I am an experienced content writer with several years of expertise in the field. Currently, I contribute to Daily Kiran, creating engaging and informative content across a variety of categories including TECHNOLOGY, health, travel, education, and automobiles. My goal is to deliver accurate, insightful, and captivating information through my words to help readers stay informed and empowered.
Leave a Comment